| Evidence based medicine: what it is and what it isn't DL Sackett, WMC Rosenberg, JAM Gray, RB Haynes, WS Richardson Bmj 312 (7023), 71-72, 1996 | 23172 | 1996 |
| Evidence-based medicine DL Sackett Seminars in perinatology 21 (1), 3-5, 1997 | 12730 | 1997 |
| Evidence-based medicine: How to practice & teach EBM RB Haynes, DL Sackett, WS Richardson, W Rosenberg, GR Langley Canadian Medical Association. Journal 157 (6), 788, 1997 | 3950 | 1997 |
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2075 | 2017 |
| Evidence based medicine: an approach to clinical problem-solving W Rosenberg, A Donald Bmj 310 (6987), 1122-1126, 1995 | 1990 | 1995 |
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection European Association For The Study Of The Liver Journal of hepatology 55 (2), 245-264, 2011 | 1556 | 2011 |
| HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection SI Khakoo, CL Thio, MP Martin, CR Brooks, X Gao, J Astemborski, ... Science 305 (5685), 872-874, 2004 | 1457 | 2004 |
| Serum markers detect the presence of liver fibrosis: a cohort study WMC Rosenberg, M Voelker, R Thiel, M Becka, A Burt, D Schuppan, ... Gastroenterology 127 (6), 1704-1713, 2004 | 1409 | 2004 |
| On the need for evidence-based medicine DL Sackett, WMC Rosenberg Journal of Public Health 17 (3), 330-334, 1995 | 1390 | 1995 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1043 | 2015 |
| Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ... Hepatology 47 (2), 455-460, 2008 | 914 | 2008 |
| Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document SA Khan, BR Davidson, R Goldin, SP Pereira, WMC Rosenberg, ... Gut 51 (suppl 6), vi1-vi9, 2002 | 905 | 2002 |
| Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update SA Khan, BR Davidson, RD Goldin, N Heaton, J Karani, SP Pereira, ... Gut 61 (12), 1657-1669, 2012 | 890 | 2012 |
| EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B: 13–14 September, 2002 Geneva, Switzerland Consensus statement (Long version) TE Jury Journal of Hepatology 39, 3-25, 2003 | 703 | 2003 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 558 | 2014 |
| Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants P Klenerman, S Rowland-Jones, S McAdam, J Edwards, S Daenke, ... Nature 369 (6479), 403-407, 1994 | 504 | 1994 |
| Medicina basada en la evidencia DL Sackett, WS Richardson, W Rosenberg, RB Haynes Elsevier Espana, 2000 | 419 | 2000 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 411 | 2014 |
| Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease J Parkes, P Roderick, S Harris, C Day, D Mutimer, J Collier, M Lombard, ... Gut 59 (9), 1245-1251, 2010 | 389 | 2010 |
| Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease A Srivastava, R Gailer, S Tanwar, P Trembling, J Parkes, A Rodger, D Suri, ... Journal of hepatology 71 (2), 371-378, 2019 | 363 | 2019 |
R Brian Haynes, OC, MD, PhDProfessor Emeritus, McMaster UniversityVerified email at mcmaster.ca
